— News and commentary from the endocrinology world

by Kristen Monaco, Senior Staff Writer, MedPage Today July 25, 2023

The shortage of weight-loss drugs now extends to liraglutide (Saxenda). (Fierce Pharma)

Compared with DPP-4 inhibitors, SGLT2 inhibitors helped reduce recurrent gout flare-ups and hospitalizations in people with type 2 diabetes. (Annals of Internal Medicine)

Along with the American Association of Clinical Chemistry, the American Diabetes Association (ADA) released an updated consensus statement on managing diabetes and standardizing diagnostic laboratory procedures. (Diabetes Care)

TikTok banned some weight-loss influencers after they talked about GLP-1 medications including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro). (Endpoints News)

Eating breakfast after 9 a.m. was linked with a 59% increased risk for developing type 2 diabetes compared with eating breakfast before 8 a.m. (International Journal of Epidemiology)

The Endocrine Society voiced opposition to proposed cuts in the House Labor, Health and Human Services, Education, and Related Agencies (Labor-HHS) funding bill "that would put life-saving endocrine research, disease prevention, and treatment at risk."

Every hour that kids ages 5 to 15 years spent watching television on average was linked with an additional 33% higher odds of developing metabolic syndrome later in life. (Pediatrics)

Older adults using semaglutide to lose weight rapidly may face special risks. (New York Times)

Can an inexpensive, 15-minute test help screen for people at risk of osteoporosis? (ACS Central Science)

The FDA again dismissed a citizen petition calling on the agency to consider banning certain endocrine-disrupting chemicals in food packaging. (Reuters)